Cheadle, UK – Carocell Bio, the UK-based company focused on the development of anti-inflammatory therapeutics, is pleased to announce that its CEO, Dr Mike Davies, will be speaking at the 2022 BIO CEO and Investor Conference, being held 14-17 February 2022 in New York, USA. Dr Davies will present on Carocell Bio, including details of its proprietary peptide-based therapeutic pipeline, on Monday 14 February from 3.15 to 3.30 pm EST. The presentation will be held in the Empire Room (7th floor) at the New York Marriot Marquis.
Carocell Bio is focused on reducing inflammation to help treat skin conditions such as burns and to help prevent scar formation after surgery, by regulating and attenuating the over-reaction of the intracellular inflammatory cascade, including the release of certain cytokines. By applying targeted proprietary peptides, in combination with advanced nanoparticle technology, a greater delivery and penetration rate in affected tissues and cells can be achieved.
One key advantage offered by Carocell Bio’s peptide technology is selectivity. Its lead peptide JEL3108 offers approximately 150-fold selectivity for p38-alpha (mitogen-activated protein kinase, MAPK) over p38-beta and 10,000-fold over other kinases This translates into a much safer and targeted therapy.
Carocell Bio has received growing interest from investors. Based upon positive results from initial data and formulation development of its lead peptide JEL3108, in November 2021 the company announced additional funding of £150,000 from Deepbridge Capital, and in June 2021 was awarded an Innovate UK Smart Grant of £270,000. Further pre-clinical data is expected to be announced by the end of Q1 2022.